VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 464 filers reported holding VALEANT PHARMACEUTICALS INTL in Q3 2014. The put-call ratio across all filers is 1.12 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2015 | $825,170,000 | +15.3% | 8,117,753 | +102.3% | 25.22% | +78.3% |
| Q3 2015 | $715,937,000 | +5.5% | 4,013,551 | +31.4% | 14.14% | +19.9% |
| Q2 2015 | $678,724,000 | +30.3% | 3,055,251 | +16.5% | 11.79% | +5.7% |
| Q1 2015 | $521,033,000 | -1.4% | 2,623,268 | -29.0% | 11.16% | -25.9% |
| Q4 2014 | $528,686,000 | -9.6% | 3,694,263 | -17.1% | 15.06% | +17.4% |
| Q3 2014 | $584,778,000 | +18.8% | 4,457,153 | +14.2% | 12.82% | -5.9% |
| Q2 2014 | $492,231,000 | +28.2% | 3,902,877 | +34.0% | 13.63% | +10.7% |
| Q1 2014 | $384,028,000 | -4.6% | 2,913,051 | -15.0% | 12.32% | -7.2% |
| Q4 2013 | $402,455,000 | +6.2% | 3,428,063 | -5.6% | 13.27% | +39.2% |
| Q3 2013 | $378,960,000 | +14.3% | 3,632,322 | -5.7% | 9.54% | -26.9% |
| Q2 2013 | $331,435,000 | – | 3,850,317 | – | 13.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chou Associates Management | 1,648,992 | $38,323,000 | 14.52% |
| Paulson & Co. | 20,839,035 | $484,299,000 | 9.89% |
| MILLER VALUE PARTNERS, LLC | 4,999,064 | $116,178,000 | 4.34% |
| GoldenTree Asset Management | 1,140,205 | $26,498,000 | 4.21% |
| Pomelo Capital LLC | 1,760,000 | $40,902,000 | 4.00% |
| Bruce & Co., Inc. | 860,000 | $19,986,000 | 3.98% |
| ValueAct Holdings | 18,033,149 | $419,090,000 | 3.79% |
| Stanley Capital Management, LLC | 318,400 | $7,400,000 | 3.25% |
| Kazazian Asset Management, LLC | 134,784 | $3,132,000 | 2.87% |
| Phoenix Investment Adviser LLC | 58,400 | $1,357,000 | 2.48% |